Eccogene

Focus: Eccogene is a Shanghai-based small molecule biotech founded in 2019, focused on infectious diseases and metabolic disorders with an early-stage pipeline.

Infectious Diseases Metabolic Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Eccogene

AI assessmentNot Hiring

No open roles listed right now. Follow Eccogene to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AZD5004

Obesity or Overweight

PHASE_1

Clinical Trials (1)

NCT06988553A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

Phase 1

Help build intelligence for Eccogene

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape drug development in high-unmet-need areas: NASH, Type 2 Diabetes, and obesity—all large commercial markets
Early-stage biotech offers hands-on impact and accelerated learning across discovery, preclinical, and early clinical phases
China-based biotech with public listing provides potential upside and stability relative to private peers

Watch Out For

Zero active job openings and no hiring pipeline signal suggests limited near-term growth or potential restructuring concerns
All pipeline programs in Phase 1 or Phase 2 with only 8 total trials—minimal validation of clinical strategy and extended timeline to value creation
Data gaps on employee count, financials, cash position, and R&D intensity create opacity on runway, burn rate, and job security

Generated by Claude from Eccogene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ECC4703

Non-alcoholic Steatohepatitis (NASH)

PHASE_1

Clinical Trials (1)

NCT05552274FTIH of ECC4703 in Healthy Volunteers

Phase 1

ECC4703 F0 formulation

Metabolic Dysfunction-Associated Steatohepatitis

PHASE_1

Clinical Trials (1)

NCT07334080ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Phase 1

Placebo

Nonalcoholic Steatohepatitis

PHASE_1

Clinical Trials (2)

NCT07505303MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Phase 2

NCT05012423FTIH Study of ECC0509 in Healthy Volunteers

Phase 1

ECC5004

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT06293742ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

Phase 1

ECC5004

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT06268145ECC5004 RBA FE Study in Healthy Participants

Phase 1

Placebo

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT05654831FTIH of ECC5004 in Healthy and Diabetic Participants

Phase 1

Placebo

Metabolic Dysfunction-associated Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT07288138A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Phase 2